secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2026-09-30T21:27:08+00:00
Accession:  0001104659-26-112420
Event type: litigation
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Liquidia says Delaware court ruled claims 1 and 14 of United Therapeutics' '327 patent valid and infringed
--------------------------------------------------------------------------------

- District Court for the District of Delaware found claims 1 and 14 of U.S. Patent No. 11,826,327 valid and infringed by Liquidia's YUTREPIA; remaining asserted claims were held invalid
- Parties must submit a proposed form of judgment specifying remedies within one week; United Therapeutics (UTHR) has sought injunctive relief restricting YUTREPIA's market availability
- CEO Roger Jeffs said Liquidia disagrees and will pursue all appellate options; the company plans an NDA supplement to remove the PH-ILD indication from YUTREPIA's label
- Liquidia said it cannot reasonably estimate the range of outcomes or financial exposure; remedies could range from removing the PH-ILD indication to broader restrictions on product availability
- Liquidia (LQDA) trades on Nasdaq; YUTREPIA was approved in 2025 for PAH and PH-ILD, and the press release was filed as Exhibit 99.1

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926112420/0001104659-26-112420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926112420/tm2626740d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-112420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer